Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada

William Herring,Isobel Pearson,Molly Purser,Hamid Reza Nakhaipour,Amin Haiderali,S Wolowacz,Kavisha Jayasundara

Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada

2014

William Herring
Isobel Pearson
Molly Purser
Hamid Reza Nakhaipour
Amin Haiderali
S Wolowacz
Kavisha Jayasundara

Objective Our objective was to estimate the cost effectiveness of ofatumumab plus chlorambucil (OChl) versus chlorambucil in patients with chronic lymphocytic leukaemia for whom fludarabine-based therapies are considered inappropriate from the perspective of the publicly funded healthcare system in Canada.

Keywords:

Ofatumumab
Intensive care medicine
Quality-adjusted life year
Chlorambucil
Progressive multifocal leukoencephalopathy
Lymphocytic leukaemia
Fludarabine
Medicine
Oncology
in patient
cost effectiveness
Operations management
first line
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations